AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 37.74M shares outstanding
USAN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases.
It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease.
The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Eric Easom
Co-Founder, Chief Executive Officer, President & Chairman of the Board
Gilbert Lynn Marks, M.D.
Class I Director
Joseph Zakrzewski
Co-Founder & Independent Director
Kabeer Aziz
Class I Director
Employees
22
Country
US
Sector
Healthcare
Website
an2therapeutics.com
Loading congressional disclosures…
based on 37.74M shares outstanding
US30d Avg
306.38K
60d Avg
261.70K
90d Avg
236.43K
